

WOMEN'S AND MEN'S HEALTH IV PANEL

EDITORIAL BOARD LIAISON

Anne L. Hume, Pharm.D., FCCP, BCPS

Professor of Pharmacy

Department of Pharmacy Practice

University of Rhode Island

Kingston, Rhode Island

Adjunct Professor of Family Medicine

Alpert School of Medicine at Brown University

Providence, Rhode Island

DRUG-INDUCED OSTEOPOROSIS

Authors

Susan K. Bowles, Pharm.D., MSc, FCCP

Associate Professor

College of Pharmacy and Department of Medicine

Dalhousie University

Clinical Coordinator – Geriatrics and Mental Health

Department of Pharmacy

Capital District health Authority

Halifax, Nova Scotia, Canada

Reviewers

Mary Beth O'Connell, Pharm.D., FCCP, FASHP, BCPS

Associate Professor

Department of Pharmacy Practice

Wayne State University

Eugene Applebaum College of Pharmacy and

Health Sciences

Detroit, Michigan

Michelle M. Richardson, Pharm.D., FCCP, BCPS

Special and Scientific Staff

William B. Schwartz Division of Nephrology

Tufts Medical Center

Assistant Professor of Medicine

Tufts University School of Medicine

Boston, Massachusetts

BREAST CANCER TREATMENT-RELATED CARDIOVASCULAR TOXICITY

Author

Audrea H. Szabatura, Pharm.D., BCOP

Oncology Medication Safety Officer

Department of Pharmacy

Dana-Farber Cancer Institute

Boston, Massachusetts

Reviewers

Lai Kit Chai, Pharm.D., BCPS

Clinical Pharmacist (ICU)

Department of Pharmacy

Kaweah Delta Medical Center

Visalia, California

Judy W.M. Cheng, Pharm.D., MPH, FCCP, BCPS (AQ
Cardiology)

Professor of Pharmacy Practice

Department of Pharmacy Practice

Massachusetts College of Pharmacy and Health Sciences

Clinical Pharmacist

Department of Pharmacy

Brigham and Women's Hospital

Boston, Massachusetts

Laura Boehnke Michaud, Pharm.D., FASHP, BCOP

Manager, Clinical Pharmacy Services

Division of Pharmacy

The University of Texas M.D. Anderson Cancer Center

Houston, Texas

DIETARY SUPPLEMENTS IN WOMEN'S AND MEN'S HEALTH

Authors

Kelly M. Shields, Pharm.D.

Associate Professor of Pharmacy Practice

Department of Pharmacy Practice

Raabe College of Pharmacy

Ohio Northern University

Ada, Ohio

Reviewers

J. Nile Barnes, Pharm.D., BCPS
Clinical Assistant Professor
Pharmacy Practice Division
College of Pharmacy
The University of Texas at Austin
Austin, Texas

Marianne McCollum, Ph.D., BSP Pharm, BCPS
Assistant Dean for Assessment
School of Pharmacy
Rueckert-Hartman College for Health Professions
Regis University
Denver, Colorado

Cydney E. McQueen, Pharm.D.
Clinical Associate Professor
Division of Pharmacy Practice and Administration
University of Missouri–Kansas City
School of Pharmacy
Kansas City, Missouri

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 3, Women's and Men's Health IV chapters:

Nicola G. Dahl, Pharm.D.
Medical Writer
Kanab, Utah

Julia Elenbaas, Pharm.D.
Belton, Missouri

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Susan Bowles (Merck Frosst Canada, Ltd.); Thomas Brown (spouse or significant other); Shareen El-Ibiary (ACCP, Women's Health Leadership Council, *Conceive Magazine*); Erika Ernst (American Board of Medical Specialties); Sally Guthrie (Eli Lilly); Jennifer Hagerman (Gilead Sciences); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid, Arkansas Foundation for Medical Care); Michael Klepser (National Institute of Allergy and Infectious Diseases); David Lourwood (Institute for Community Health Education, First Data Bank); Andrea Luisi (Tarascon Pharmacopoeia); William McIntyre (American Cancer Society, American Heart Association); Ian McNicholl (Bristol-Myers Squibb); Cydney McQueen (First Data Bank, Therapeutic Faculties, Inc.); Laura Boehnke Michaud (National Comprehensive Cancer Network, GlaxoSmithKline, ProStrakan, AstraZeneca, Bristol-Myers Squibb); Mary Beth O'Connell (National Institutes of Health, Office of Research on Women's Health, Association of Reproductive Medicine, ASHP); Kelly Ragucci (Wyeth); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, *Annals of Pharmacotherapy*); Jeffrey T. Sherer (Sturge-Weber Foundation); Martha Stassinis (Veterans Administration); Kristina Ward (Rhode Island Medical Assistance Pharmacy and Therapeutics Committee)

Stock Ownership: Lai Kit Chai (Tenet Healthcare Corp.); Katherine H. Chessman (Procter & Gamble [spouse or significant other]); Lisa C. Hutchison (Cardinal Health); Emilie Karpiuk (Cardinal Health); Andrea Luisi ([spouse or significant other] Merck, Pfizer, Medco, CVS)

Royalties: Lisa C. Hutchison (ASHP); Cydney McQueen (ASHP); Kelly Shields (Pearson Health Sciences)

Grants: Susan Bowles (Roche); Judy W.M. Cheng (St. Jude's Medical Research Center); Shareen El-Ibiary (University of California, San Francisco, Roche-Affamatrix); Erika Ernst

(Pfizer Pharmaceuticals [two grants], Merck and Co.); Patty Fan-Havard (Abbott); Alexander Guirguis (Tennessee Department of Health [two grants]); Brian A. Hemstreet (AstraZeneca); Anne Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer Ingelheim, National Institutes of Health); Courtney Jarvis (Barr Laboratories, Myers Primary Care Institute, University of Massachusetts Medical School/Memorial Medical Center); Michael Klepser (Gilead Sciences); Laura Boehnke Michaud (GlaxoSmithKline, Abraxis Oncology); Mary Beth O'Connell (Merck); Kelly Ragucci (Pfizer, Inc.); Erin C. Raney (Procter and Gamble); Michelle Richardson (NIH NIDDK [two grants]); Justin Sherman (Louisiana Campaign for Tobacco-Free Living); Kristina Ward (Quality Partners of Rhode Island, University of Massachusetts Memorial Healthcare)

Honoraria: Susan Bowles (Pfizer Canada, Lundbeck Canada, Merck Frosst Canada, Ltd.); Dana Brown (Pfizer); Thomas Brown (Pfizer, Sanofi-Aventis [spouse or significant other]); Doshia Cummins (Abbot Pharmaceuticals); Shareen El-Ibiary (ACCP, APhA, Florida Agricultural and Mechanical University); Sally Guthrie (Scius Medical, Bristol-Myers Squibb); Lisa C. Hutchison (ACCP, ASHP); Kristi Kelley (Eli Lilly/Amylin Pharmaceuticals, Pfizer); David Lourwood (Pfizer, Inc., Institute for Community Health Education); Ian McNicholl (Bristol-Myers Squibb, GlaxoSmithKline, Tibotec Therapeutics); Mary Beth O'Connell (Roche); Louise Parent-Stevens (APhA); Erin C. Raney (American Diabetes Association); Michelle Richardson (Amgen); Justin Sherman (ACCP)

Other: Nothing to Disclose: J. Nile Barnes, Clarence Chant, Martha Fankhauser, Kelly Killius, Kristen Lamberjack, Marianne McCollum, Anna Morin, Sarah Shrader, Audrea Szabatura

ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmacy Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm.

Other questions regarding recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591
www.bpsweb.org